Overall, our data indicates that the MAPT P301S mutation and accumulation of pTau are associated with distinct brain lipidomes in vivo, further implicating altered lipid metabolism as a potential pathogenic and druggable process in primary tauopathies. The gene discussed is MAPT; the disease is tauopathy.